BACKGROUND Cachexia involves unintentional body weight loss including diminished muscle and adipose tissue mass and is associated with an underlying disease. Systemic overexpression of IL-6 accelerates cachexia in the Apc(Min/+) mouse, but does not induce wasting in control C57BL/6 mice. With many chronic diseases, chronic inflammation and metabolic dysfunction can be improved with moderate exe...

Cancer cachexia is a severe and disabling clinical condition that frequently accompanies the development of many types of cancer. Muscle wasting is the hallmark of cancer cachexia and is associated with serious clinical consequences such as physical impairment, poor quality of life, reduced tolerance to treatments and shorter survival. Cancer cachexia may evolve through different stages of clin...

Approximately half of all cancer patients present with cachexia, a condition in which disease-associated metabolic changes lead to a severe loss of skeletal muscle mass. Working toward an integrated and mechanistic view of cancer cachexia, we investigated the hypothesis that cancer promotes mitochondrial uncoupling in skeletal muscle. We subjected mice to in vivo phosphorous-31 nuclear magnetic...

Cancer cachexia is a debilitating multi-factorial wasting syndrome characterised by severe skeletal muscle and dysfunction (i.e., myopathy). In the oncology setting, arises from synergistic insults both cancer–host interactions chemotherapy-related toxicity. The majority of studies have surrounded interaction side cancer cachexia, often overlooking capability chemotherapy to induce cachectic my...

This paper presents a data mining application in metabolomics. It aims at building an enhanced machine learning classifier that can be used for diagnosing cachexia syndrome and identifying its involved biomarkers. To achieve this goal, a data-driven analysis is carried out using a public dataset consisting of 1H-NMR metabolite profile. This dataset suffers from the problem of imbalanced classes...

1. Matsuo Y, Gleitsmann K, Mangner N, Werner S, Fischer T, Bowen TS, et al. Fibronectin type III domain containing 5 expression in skeletal muscle in chronic heart failure-relevance of inflammatory cytokines. J Cachexia Sarcopenia Muscle 2015;6:62–72. 2. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr 2008;27:793–799. 3. von Haehling...

Cancer-related anorexia and cachexia syndrome (CACS) is a complex multifactorial condition, with loss of lean body mass, chronic inflammation, severe metabolic derangements, reduced food intake, reduced physical activity, and poor quality of life as key symptoms. Cachexia recognizes different phases or stages, moving from precachexia through overt cachexia to advanced or refractory cachexia. Th...

Introduction. Cachexia is a syndrome characterized by the loss of musculoskeletal mass, with or without adipose which cannot be reversed nutritional support. In Chile, there are no data on cachexia in cancer patients that allows for decision making better interdisciplinary management. this study, prevalence inpatient and outpatient was investigated. Methods. An observational, descriptive, cross...

Cachexia causes weight loss and increased mortality. It affects more than 5 million persons in the United States. Other causes of weight loss include anorexia, sarcopenia, and dehydration. The pathophysiology of cachexia is reviewed in this article. The major cause appears to be cytokine excess. Other potential mediators include testosterone and insulin-like growth factor I deficiency, excess m...

cer, acute nonlymphocytic leukemia, and sarcomas have a low frequency of weight loss (31–40%) (16). This suggests that cachexia-inducing tumors may have an altered genetic expression that allows them to produce factors that degrade triglyceride stores in adipose tissue and myofibrillar proteins in skeletal muscle. Certainly cachexia bears no simple correlation to tumor burden, metastasis, or an...